Literature DB >> 1635563

Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: comparison of deglycosylation by tunicamycin treatment and genetic engineering.

S M Hobbs1, L E Jackson, J Hoadley.   

Abstract

The role of carbohydrate in the structure and function of immuno-globulin Fc regions has been studied using the interaction of a monoclonal mouse IgG2b anti-NIP antibody with the IgG Fc transport receptor from neonatal rat gut. An aglycosyl variant of this immunoglobulin, in which site-directed mutagenesis had been used to eliminate the carbohydrate attachment site in the CH2 domain by changing Asn297 to Ala, was compared in this system to aglycosyl immunoglobulin prepared from immunoglobulin-secreting cells treated with tunicamycin to inhibit N-linked glycosylation. Loss of carbohydrate from the heavy chain was confirmed for both methods by Western blotting of the separated chains with Concanavalin A, and no significant differences in circular dichroism spectra were found between glycosylated and non-glycosylated mutants. Removal of carbohydrate by site-directed mutagenesis had no effect on binding of the immunoglobulin to the Fc transport receptor (FcTR) in vitro or transport from the gut to blood in vivo. Short-term clearance from circulation and degradation by gut contents in vitro were similarly unaffected. Mutation of Glu235 to Leu, an alteration that allows binding to human monocyte Fc gamma RI, did not alter the interaction with FcTR. However, treatment of wild-type or aglycosyl mutant cells with tunicamycin resulted in immunoglobulin which was less stable, cleared more rapidly and was transported slightly less efficiently. These findings indicate that the binding site for the FcTR may be unique among Fc-binding ligands, and that tunicamycin treatment may cause alterations in the immunoglobulin molecule in addition to loss of N-linked carbohydrate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1635563     DOI: 10.1016/0161-5890(92)90133-i

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Ileal Immunoglobulin Binding by the Neonatal Fc Receptor: A Previously Unrecognized Mechanism of Protection in the Neonatal Rat Model of Necrotizing Enterocolitis?

Authors:  Jonathan R Swanson; Tamas Jilling; Jing Lu; Jessica B Landseadel; Marek Marcinkiewicz; Phillip V Gordon
Journal:  EJ Neonatol Res       Date:  2011-03-03

2.  Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice.

Authors:  Rachel A Karlnoski; Arnon Rosenthal; Jennifer Alamed; Victoria Ronan; Marcia N Gordon; Paul E Gottschall; Jan Grimm; Jaume Pons; Dave Morgan
Journal:  J Neuroimmune Pharmacol       Date:  2008-07-08       Impact factor: 4.147

3.  Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies.

Authors:  Sheng Yin; Cinthia V Pastuskovas; Leslie A Khawli; John T Stults
Journal:  Pharm Res       Date:  2012-09-06       Impact factor: 4.200

4.  Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice.

Authors:  Niki C Carty; Donna M Wilcock; Arnon Rosenthal; Jan Grimm; Jaume Pons; Victoria Ronan; Paul E Gottschall; Marcia N Gordon; Dave Morgan
Journal:  J Neuroinflammation       Date:  2006-05-10       Impact factor: 8.322

5.  Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.

Authors:  Cheng Luo; Song Chen; Na Xu; Chi Wang; Wen Bo Sai; Wei Zhao; Ying Chun Li; Xiao Jing Hu; Hong Tian; Xiang Dong Gao; Wen Bing Yao
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.